TY - JOUR
T1 - Rubidazone vs adriamycin
T2 - An evaluation of their differential toxicity in the spleen colony assay system
AU - Alberts, D. S.
AU - Van Daalen Wetters, T.
N1 - Funding Information:
This investigation was supported in part by the Medical Oncology Program Project Grant CA-17094 (to the University of Arizona) from the National Cancer Institute, National Institutes of Health, Bethesda, Maryland; the Faculty Training Grant in Clinical Pharmacology from the Pharmaceutical Manufacturing Associa- tion, Washington, D.C.; and the Cancer Coordinating Committee Grant from the University of California, Berkeley, California.We wish to thank Drs R. Maral,
PY - 1976/7
Y1 - 1976/7
N2 - Rubidazone, the new semi-synthetic benzol hydrazone hydrochloride derivative of dauorubicin, has proved on a molecular weight basis to be less toxic than adriamycin and similar to daunorubicin in cardiac toxicity studies in the hamster as well as in other in vivo and in vitro test systems. It has proven effectiveness against several animal tumours and human acute leukaemias. We have compared the inhibitory effect of rubidazone to that of adriamycin on P388 leukaemia and normal bone marrow colony-forming units (CFU) using the spleen colony assay system in male DBA2 mice. The efficacy ratios (i.e., the ratio of the slopes of the normal bone marrow CFU to leukaemic CFU dose-survival curves) in the spleen colony assay system for rubidazone and adriamycin were 7-8 and 7-5 respectively. This near identity of efficacy ratios fro rubidazone and adriamycin correlated with the results of median survival time studies in the leukaemic mice. Their dose-median survival time curves were almost parallel, having nearly identical slopes. Rubidazone's equal therapeutic index as compared to adriamycin in the spleen colony assay system together with its known decreased toxicity to cardiac muscle cells makes it an extremely promising new anthracycline derivative to study in comparison to adriamycin in human malignancies.
AB - Rubidazone, the new semi-synthetic benzol hydrazone hydrochloride derivative of dauorubicin, has proved on a molecular weight basis to be less toxic than adriamycin and similar to daunorubicin in cardiac toxicity studies in the hamster as well as in other in vivo and in vitro test systems. It has proven effectiveness against several animal tumours and human acute leukaemias. We have compared the inhibitory effect of rubidazone to that of adriamycin on P388 leukaemia and normal bone marrow colony-forming units (CFU) using the spleen colony assay system in male DBA2 mice. The efficacy ratios (i.e., the ratio of the slopes of the normal bone marrow CFU to leukaemic CFU dose-survival curves) in the spleen colony assay system for rubidazone and adriamycin were 7-8 and 7-5 respectively. This near identity of efficacy ratios fro rubidazone and adriamycin correlated with the results of median survival time studies in the leukaemic mice. Their dose-median survival time curves were almost parallel, having nearly identical slopes. Rubidazone's equal therapeutic index as compared to adriamycin in the spleen colony assay system together with its known decreased toxicity to cardiac muscle cells makes it an extremely promising new anthracycline derivative to study in comparison to adriamycin in human malignancies.
UR - http://www.scopus.com/inward/record.url?scp=0017182544&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0017182544&partnerID=8YFLogxK
U2 - 10.1038/bjc.1976.123
DO - 10.1038/bjc.1976.123
M3 - Article
C2 - 952715
AN - SCOPUS:0017182544
VL - 34
SP - 64
EP - 68
JO - British Journal of Cancer
JF - British Journal of Cancer
SN - 0007-0920
IS - 1
ER -